See the attached the educational slides of Prof Spyridonidis presentation at 49th EBMT annual meeting, Paris 2023_GVHD prophylaxis in matched sibling donor transplant_PTCY_Spyridonidis

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40 mins Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial

49 Annual Meeting of the EBMT - 23-26 April, 2023, Paris France Relapse remains a major cause of failure after allogeneic hematopoietic cell trnaplantation (allo-HCT). Prophylactic donor lymphocyte infusion (pDLI) could be used to reduce relapse. However, its widespread application has been restricted...

49 Annual Meeting of the EBMT - 23-26 April, 2023, Paris France Though a randomized study suggested the benefit of in vivo T-cell depletion (TCD) as Graft versus Host Disease (GvHD) prophylaxis in matched sibling donor (MSD) allogeneic hematopoietic cell transplantation...

March 19–March 22, 2023 Munich, Germany https://www.dropbox.com/s/10uojri60ijyazs/Leukemia%20MUnich%20selected.pptx?dl=0

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40 mins The optimal selection of patients with acute myeloid leukemia (AML) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an area of research that continues to evolve.1 For patients with favorable-risk AML who achieve...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 35 Mins Understanding how genetic variants impact molecular phenotypes is a key goal of functional genomics, currently hindered by reliance on a single haploid reference genome. Here, we present the EN-TEx resource of 1,635 open-access datasets...

1. Lesson Plan_Pre-clinical studies design 2. Pre-clinical studies - An overview - Ariel Angel 11.2022 3. Tech Transfer

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration:40mins https://www.bloodtransfusion.it/bt/article/view/332

https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/hematologic-cancers-treatment-regimens/leukemia-treatment-regimens-acute-lymphoblastic-leukemia-all/ NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40mins Axicabtagene ciloleucel is an engineered autologous anti-CD19 chimeric antigen receptor T cell therapy being developed for patients with refractory aggressive B-cell lymphoma. The product is manufactured in a central facility from cellular starting material containing...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40 mins In this registry-based study, we compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) transplanted in first complete remission (CR-1), following conditioning with total body irradiation...

Administration and handling of cell product Management of Adverse Events Patient card

Find attached the article ''To Transplant or Not To Transplant in First Remission Acute Lymphoblastic Leukemia? Study group data give some answers, but not all.'' authored by Prof. Spyridonidis and published at American Society for Transplantation and Cellular Therapy

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 40 mins Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (alloHCT) is recommended in first complete remission (CR1). However, in the...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 35 mins With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for...

Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou Duration: 40 mins